Werewolf S-4 Amendment Sets Proxy Vote on $500M Ambros Reverse Merger and $150M PIPE
HOWL has more than doubled off its 52-week low of $0.27 on light trading volume (0.1× avg).
Summary
Werewolf's amended S-4 turns the Ambros reverse merger into a formal proxy vote, disclosing that current Werewolf holders would keep only about 6.4% of the combined company, with Ambros holders at 72.0% and PIPE investors at 21.6%. Closing hinges on a $150 million PIPE (minimum $100 million) and Nasdaq listing approval requiring a $4.00 post-split bid price.
Key Events · M&A and Partnerships · HOWL
-
Proxy Filed for Ambros Reverse Merger
Amendment No. 1 to the Form S-4 is a preliminary proxy statement/prospectus for a special meeting at which holders must approve the Nasdaq stock issuance, the change of control, an authorized share increase, a reverse split and the name change to Ambros Therapeutics, Inc.
-
Werewolf Holders Cut to ~6.4%
Immediately after the merger, pre-merger Werewolf holders (excluding PIPE participants) are expected to own about 6.4% of the combined company, Ambros holders about 72.0% and PIPE investors about 21.6%, on a fully diluted basis.
-
$150M PIPE With $100M Minimum
Investors committed $150.0 million in the Concurrent PIPE Financing, but the merger cannot close unless at least $100.0 million (less expenses) is actually received; the PIPE buys Werewolf shares and $0.001-strike pre-funded warrants.
-
Nasdaq $4.00 Bid Condition
Approval of the Nasdaq listing application requires the combined company to maintain a minimum bid price of $4.00 or higher for a period after the reverse split; Werewolf has not regained the $1.00 minimum bid compliance and its additional window expires February 1, 2027.
Analysis · HOWL · Life Sciences
Investors finally get the numbers they previously had to guess at, because this proxy statement/prospectus is what actually puts the reverse merger to a shareholder vote. Existing HOWL holders would be left with roughly 6.4% of the combined company, while Ambros holders take about 72.0% and PIPE investors about 21.6% — a near-total change of control. Closing depends on the PIPE raising at least $100 million of the $150 million committed, and the combined company must clear Nasdaq's initial listing bar, which the filing says requires a $4.00 minimum bid price after a reverse split. Werewolf's own position is dire: a going-concern warning, $22.0 million of cash at June 30, 2026, and a Nasdaq minimum-bid deficiency it has not cured, with the additional compliance window running to February 1, 2027. Should the merger fail, the filing states Werewolf would need new funding and may have to dissolve. Ambros brings neridronate in a Phase 3 CRPS-1 trial and $103.2 million of cash, which the filing says funds operations into the first half of 2029 with the PIPE proceeds.
How filings like this one have moved
In the 30 days to Oct 26, 2026, 36.2% of the 898 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.75%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, HOWL was trading at $0.98 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $47.7M. The 52-week trading range was $0.27 to $1.83. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.